LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to evaluate Sentien’s ex vivo cell therapy, SBI-101, in patients suffering from acute kidney injury (AKI) associated with sepsis.  This patient population includes COVID-19 patients with sepsis-AKI.

The BARDA-Sentien collaboration will enable evaluation of high dose SBI-101 therapy for the first time and support regulatory path activities to advance its development for the treatment of sepsis.

Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19.  SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

In addition, the independent Data Safety Monitoring Board has reviewed the safety data from the first cohort and supports continuation of the study and dose escalation.

Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the first subject has been enrolled in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19 at the University of New Mexico (UNM) Hospital.  SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).

Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, has been awarded a $2.4 million contract from the Medical Technology Enterprise Consortium (MTEC).  The funds will be used to support the development of a potency assay for mesenchymal stromal cells (MSCs) in regenerative medicine products. Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19.  Approval of this IND allows Sentien to initiate a Phase 1/2 study with a focus on COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT). Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer.  Dr. Nissenson will join Sentien’s executive team and oversee the clinical development of Sentien’s lead product, SBI-101.  Dr. Nissenson serves as an Emeritus Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, Emeritus Chief Medical Officer of DaVita Kidney Care, and a member of the Board of Directors of Angion Biomedica Corp and Rockwell Medical, Inc. Read More >

LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive Chairman.  Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has filled for the past nine years, as well as work closely with CEO Brian Miller and Sentien’s management team. Read More >